文献速递神经肿瘤小儿神经外科与脑积水

来那度胺联合放疗治疗儿童弥漫内生型脑桥胶质瘤或高级别胶质瘤的I期试验

A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas.
PubMed 文献 · J Neurooncol · 2020-10-11

本研究旨在确定免疫调节剂来那度胺在6周放疗期间每日给药的最大耐受剂量(MTD)或II期推荐剂量(RP2D),对象为新诊断的弥漫内生型脑桥胶质瘤(DIPG)或高级别胶质瘤(HGG)儿童和年轻成人。MTD未达到,RP2D为116 mg/m2/day,主要毒性为骨髓抑制,在较高剂量水平和较高稳态血浆浓度下观察到显著疗效。

要点

  • 来那度胺联合放疗的RP2D为116 mg/m2/day。
  • 儿童恶性胶质瘤对来那度胺的耐受剂量远高于成人。
  • 主要毒性为骨髓抑制,MTD未达到。

核心结论

  • 来那度胺在放疗期间每日给药的RP2D为116 mg/m2/day。
  • 儿童恶性胶质瘤在放疗期间对来那度胺的耐受剂量远高于成人。
  • 活性主要在较高剂量水平观察到,提示剂量反应关系。

研究设计与样本

  • I期剂量递增试验,采用标准3+3设计。
  • HGG患者要求肿瘤不可手术或未完全切除。
  • 放疗处方剂量54-59.4 Gy,同期每日来那度胺,放疗后休息2周,维持来那度胺116 mg/m2/day×21天/28天周期。
  • 24例可评估剂量(DIPG 13例,HGG 11例)。

主要发现

  • MTD未达到,剂量至116 mg/m2/day。
  • 在DIPG和恶性胶质瘤(胶质瘤病)中观察到显著疗效,尤其在较高剂量水平和较高稳态血浆浓度时。
  • 主要毒性为骨髓抑制。

关键数值与推荐

  • RP2D为116 mg/m2/day(放疗期间每日给药)。
  • 放疗剂量54-59.4 Gy。
  • 维持治疗来那度胺116 mg/m2/day×21天/28天周期。

临床怎么用

  • 儿童DIPG或HGG患者可耐受放疗期间来那度胺每日116 mg/m2/day。
  • 需监测骨髓抑制毒性。
  • 较高剂量水平可能与小部分患者的显著疗效相关。

局限性

  • I期试验主要目的为剂量探索,疗效需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study was performed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of the immunomodulatory agent, lenalidomide, when administered daily during 6 weeks of radiation therapy to children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) PATIENTS & METHODS: Children and young adults < 22 years of age with newly diagnosed disease and no prior chemotherapy or radiation therapy were eligible. Children with HGG were required to have an inoperable or incompletely resected tumor. Eligible patients received standard radiation therapy to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide daily during radiation therapy in a standard 3 + 3 Phase I dose escalation design. Following completion of radiation therapy, patients had a 2-week break followed by maintenance lenalidomide at 116 mg/m2/day × 21 days of a 28-day cycle. RESULTS: Twenty-nine patients (age range 4-19 years) were enrolled; 24 were evaluable for dose finding (DIPG, n = 13; HGG, n = 11). The MTD was not reached at doses of lenalidomide up to 116 mg/m2/day. Exceptional responses were noted in DIPG and malignant glioma (gliomatosis cerebri) notably at higher dose levels and at higher steady state plasma concentrations. The primary toxicity was myelosuppression. CONCLUSION: The RP2D of lenalidomide administered daily during radiation therapy is 116 mg/m2/day. Children with malignant gliomas tolerate much higher doses of lenalidomide during radiation therapy compared to adults. This finding is critical as activity was observed primarily at higher dose levels suggesting a dose response.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hipp SJ, Goldman S, Kaushal A, et al. A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. J Neurooncol. 2020. PMID: 33040274. doi:10.1007/s11060-020-03627-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。